How do you see the future direction of the medical disposal sector?

China has not paid enough attention to the disposal of medical waste for a long time, the construction of centralized disposal facilities is seriously lagging behind, and most of the hazardous waste is in a state of low-level comprehensive utilization, simple storage or direct discharge. Specifically, there are five main ways to deal with it, that is, selling medical waste to hawkers, discarding medical waste at will, mixing medical waste with domestic waste, directly incinerating and landfilling medical waste, and centralizing the treatment of medical waste. Due to the lack of supervision and lax management, the above five treatment methods all have different degrees of hidden dangers, which may seriously endanger human health.

More worryingly, the amount of medical waste generated is increasing significantly, further exacerbating the pressure on medical waste disposal. Data show that the amount of medical waste generated in China has increased from 10,000 tons in 2005 to 10,000 tons in 2016.

However, the problems with the way medical waste is disposed of and the increase in the amount of it is generated, indicating that there is a great opportunity in the medical waste treatment industry. According to this estimate, in 2016, the scale of China's medical waste treatment market reached 100 million yuan, and it still maintains a rapid development trend. With the improvement of medical services, there is still a lot of room for improvement in the medical waste treatment industry, and the prospects are promising.

Nowadays, people's health awareness is gradually increasing, and the pursuit of quality of life has become a major trend. With the country's attention to the health care industry, various pharmaceutical-related policies such as the New Year in January will be introduced a lot, and the support is getting bigger and bigger, and the investment is increasing, which will be good for the development of the health care industry for a long time. **For products, ICBC Healthcare is recommended**, which is the best return in the same theme in the market this year, nearly 15%, and the prospects are good.

After the year, the medical sector will not be **, and the medical sector will not be **, also because there is too much need.

Then whether the medical sector will be ** depends on the ** at that time to decide.

After the year, the medical sector will not be **, it may be**.

After the year, the medical sector is likely to rise and may rise.

Possibly. China's economy is expected to decline.

I don't know much about this specifically, it shouldn't be**.

Epidemic prevention and control is still ongoing. The epidemic abroad has not completely passed.

From the perspective of thematic investment, the pharmaceutical sector during the outbreak of the epidemic is in a hot state, and the epidemic is still ongoing, so the medical sector is still active. is the reason for the current existence.

The healthcare sector had the highest relative cumulative excess return during the outbreak of the pandemic, far outpacing other sectors. Compared with other sectors, there is also the continuous progress of epidemic prevention and control, so it is sought after by short-term thematic investment funds.

Experience by analogy. During the SARS epidemic in 2003, public protection, medical personnel protection, vaccines, and drugs included: hormones (glucocorticoids.

Antiviral Chinese medicine (e.g. Radix Radix.

and other demand will be significantly increased in the amount of virus transmission, related companies in the capital market.

have also benefited from the rotation of the SARS theme. So by analogy, this time it is still a lot of investment in medicine.

Because taking into account this pneumonia.

The molecular structure of the virus has high homology with that of SARS in 2003. At present, although the domestic control is stable, the epidemic situation abroad is still very serious, and a large number of medicines and protective materials are still needed, so the current time is still a good time to develop related companies. Therefore, judging from the situation of this pneumonia, the current A shares.

Listed companies involved in this theme include: public protection (leading shares, TEDA shares, Golden Eagle shares, Shenda shares, Changshan.

Beiming, etc.), medical protective consumables (Zhende Medical, Yingke Medical, Ogilvy Medical, Bluesail Medical), vaccines (Kangtai Biotechnology, Hualan Biotechnology), diagnostic testing (BGI.

AutoNavi Infrared, Dali Technology), glucocorticoids (Modern Pharmaceutical, Xianju Pharmaceutical), antiviral drugs (Rhine Biotechnology), traditional Chinese medicine (Baiyunshan, Yiling Pharmaceutical, Xiangxue Pharmaceutical), etc.

The outbreak of the epidemic will have a negative impact on the ** market in the short term.

Forming a shock (the macro economy is affected as a result), and in the short term, there will be emotional fluctuations in industries where consumers such as transportation and social services are concentrated. However, this short-term impact will strengthen the market's confidence in countercyclical operations, so we will continue to recommend high-growth, high-elastic and high-valuation hard technology and new consumption throughout the year. The medical sector is currently relatively hot.

The reason behind the skyrocketing medical ** is because the R&D capabilities of pharmaceutical companies are getting stronger and stronger.

In fact, entering 2020, due to the impact of the epidemic, the macro environment is also full of variables, although the performance growth rate of the pharmaceutical sector has continued to decline in the past two years this year, investors are more interested in the pharmaceutical sector and are more willing to invest money in these sectors. In recent times, the valuation of some sectors has approached the highest value in history, such as the four sectors of medical services, medical devices, biological products, and chemical raw materials, and of course, some sectors are under historical valuation, such as pharmaceutical business and traditional Chinese medicine. Of course, on the whole, medical ** is still very popular.

So, why is the medical category so favored by investors? In fact, the reason why medical stocks will soar is mainly because the market is chasing companies with strong pharmaceutical research and development capabilities, as long as pharmaceutical stocks have strong innovation and research and development capabilities, they can be sought after by shareholders.

According to relevant research, the stock price of Pfizer, which has the core representative drugs, increased nearly 20 times during the sales period from 1990 to 2000, but it has less than doubled since 2000. If the R&D of innovative drugs is divided into a certain stage, it can be divided into a theoretical accumulation period, a R&D breakthrough period, a sales period and a recession period. For a pharmaceutical company, as long as the sales period is the first period, it can basically lie down and make money, and this stage is also the first period of the pharmaceutical company, and the stock price will also skyrocket.

However, when the pharmaceutical company passes the sales period, it will enter a period of recession, basically stagnating, if it cannot develop new innovative drugs, the pharmaceutical company will face the crisis of bankruptcy, and the stock price will continue to be the first.

In recent years, many pharmaceutical companies in China are in a new round of R&D breakthrough period, as long as they pass this stage, there will be many innovative drugs coming out, and pharmaceutical companies will also enter the first period. More importantly, the state has special support for the research of major innovative drugs, and the domestic innovative drug research and development capabilities have also been greatly improved. It is worth mentioning that, according to relevant data, from 2014 to 2017, there were nearly 70 drugs in phase III clinical trials on average every year, and a new drug entering phase III clinical trials means that there is a 45% probability that it can be marketed.

In fact, since 2015, the state has formulated many policies to create a better R&D environment for pharmaceutical and biological enterprises and vigorously support the development of innovative drugs.

All in all, the reason behind the skyrocketing medical ** is because of the increasing R&D capabilities of pharmaceutical companies.

The reason is that during the epidemic, many medical device and drug companies have been given development opportunities, and the future prospects are also very good, so the medical category has skyrocketed.

The reason for the sharp rise in medical ** is the impact of the epidemic and the current progress in vaccine research and development, which have driven the related ** surge.

Now that we are in the midst of the new crown epidemic, a large number of medical appliances and equipment are needed, so the medical category has skyrocketed.

With the development of biomedical materials in China and the policy environment of "new medical reform", the localization of medical devices is just around the corner. It is understood that biomedical materials are divided into many branches such as metal materials, polymer materials, medical ceramics, and composite materials. Among them, metal materials are mainly used for the replacement of artificial bones and joints, which is the most widely used type of biomedical materials, and is also the largest category of biomedical materials in the current market share.

The second is medical ceramics and polymer materials, which are used similarly to metal materials, and are mainly used for the repair and replacement of hard tissues.

Relevant public information shows that domestic high-end medical devices have long been monopolized by imported products, especially nuclear magnetic resonance (MR), CT, molecular imaging (PET-CT) and other highly technology-intensive equipment, according to the prospective industry research institute's "2015-2020 China medical device industry market demand and investment strategic planning analysis report prospect" data show that in the field of medical devices in China, about 80% of the CT market, 90% of the ultrasonic instrument market, 85% of the inspection instrument market, 90% Magnetic resonance equipment, 90% of the ECG machine market, 80% of the high-end monitor market, and 90% of the high-end physiological recorder market are monopolized by foreign-funded enterprises. It is undeniable that the introduction of high-end equipment is of great significance for improving the diagnostic technology of the hospital and improving the level of medical services, but it is followed by high examination costs, taking CT as an example, it is relatively expensive to bring tens of millions of CT examinations, as far as the current market price is concerned, CT examination of a part of the ** is about 300 yuan. The prospective industry research institute listed the multi-layer spiral CT approved by the Jiangxi Price Bureau in 2009, and the author intercepted the head CT examination, and it can be seen that the most basic ** is 280 yuan.

The opportunity is the new time, because the military sector will be the mainstream hot spot in the past two years, and the situation in the South China Sea and the East China Sea can be shocked.

Medicine is mainly defensive, as long as it does not rise sharply, there will be more or less opportunities in the later stage.

Someone will take over the market before it falls, and medicine makes the difference.

1.The economic strength of the enterprise. 2.The development potential of the enterprise. 3.The technical strength of the enterprise. 4.The integrity of the business. 5.The direction of business management decisions. 6.Scientific institutionalization.

What kind of direction are you talking about, if there are no special circumstances, China, the development of enterprises will be very rapid! Especially after the financial crisis......Some companies are recovering very quickly, but they have also given small companies some opportunities, and it has brought a major reshuffle to the society! Let small and medium-sized enterprises develop rapidly!

Go with your feelings.

I think the engine may get better and better in the future, but now some engines are very noisy, and some people drive that kind of ghost fire motorcycle at night, and then it is very noisy, and there are often such people at night, and then they can't sleep.

In my own personal experience, I think the future of engines is particularly good, because there will be a lot of demand for engines in the future.

At present, the main fuel of the engine is oil, and according to the current earth's resources, the future engine will definitely be transformed to other renewable resources, so that the engine can operate normally without oil.

I think that in the future, the engine will develop better and better, and as the engine performance improves, the scope of development will gradually expand.

In the process of going to the countryside, I personally experienced the feeding of pigs and cattle in the countryside, which I had not experienced before in the city, and I couldn't even see the cattle in the city, I thought it was quite interesting, and it was also the first time that I had such a close contact with this kind of poultry animal.

I think the trend of engines in the future will be more advanced, for example, the current electrification will become more and more abundant. A lot of things are now replacing gasoline, such as an electric car.

I think the engines of the future will have a major change in terms of fuel, and it will become more and more important to find new energy sources that can be used, after all, oil will always run out one day.

In today's era of high-tech development, engines are becoming more and more versatile. In particular, there are more and more cars, and almost every household owns a car, so the sales of engines are also increasing.

Fuel Cell Engines: The advent of fuel cells is definitely a new era in the history of automobiles. This zero-emission, pollution-free clean energy has long been regarded by the industry as one of the development directions of future automobiles, and the first victory of the fuel cell installed in the Hyundai Tucson FCV model also indicates that the technology has gradually matured in the automotive field.

The reliability of its product quality, the size of the cost, the penetration rate of supporting infrastructure and even the market recognition require the triple efforts of the first class, manufacturers and consumers to be widely promoted.